Company Percheron Therapeutics Limited Börse Stuttgart
Equities
AWY0
AU0000317281
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0482 EUR | -0.62% | -6.23% | +40.12% |
06-17 | Percheron Therapeutics Appoints CFO | MT |
06-03 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
ATL 1102
80.4
%
| 2 | 98.1 % | 2 | 80.4 % | -11.14% |
Unallocated
19.6
%
| 0 | 1.9 % | 0 | 19.6 % | +1,026.23% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +8.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 07/05/23 |
Anthony Filippis
COO | Chief Operating Officer | - | 31/10/22 |
Andrew McKenzie
PRN | Corporate Officer/Principal | - | - |
Alicia Mellors
SEC | Corporate Secretary | - | 23/02/21 |
George Tachas
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Price
BRD | Director/Board Member | 68 | 03/10/21 |
James Garner
CEO | Chief Executive Officer | - | 07/05/23 |
Chairman | - | 21/03/21 |
Company contact information
Percheron Therapeutics Ltd.
Collins Place 35 Collins Street
3000, Melbourne
+61 3 9827 8999
http://www.PercheronTx.comSector
Sales per Business
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- PER Stock
- AWY0 Stock
- Company Percheron Therapeutics Limited